GlassScriptPhysician profile
Mia L Scott
NPI 1215019724
$53,186.68
in general payments reported to CMS, 2019-2025
29 companies · $1,605 in 2025
The $1,605 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,984 · 2020: $4,219 · 2021: $15K · 2022: $18K · 2023: $2,068 · 2024: $1,578 · 2025: $1,605.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,252.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,251.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $36,697.98 | 2019-2025 | Dovato, Apretude, Rukobia |
| Gilead Sciences, INC. | $9,281.76 | 2019-2025 | Biktarvy |
| Theratechnologies INC. | $3,559.51 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $948.97 | 2019-2025 | Delstrigo, Pifeltro, Capvaxive |
| Janssen Scientific Affairs, LLC | $465.98 | 2019-2023 | Symtuza |
| Allergan, INC. | $403.07 | 2019-2020 | |
| Janssen Biotech, INC. | $267.56 | 2019-2023 | Symtuza |
| Amarin Pharma, INC. | $222.28 | 2019-2020 | |
| Novo Nordisk INC | $210.90 | 2019-2021 | |
| Abbvie INC. | $192.83 | 2019-2023 | Mavyret |
| Astrazeneca Pharmaceuticals LP | $149.13 | 2019-2020 | |
| Lilly USA, LLC | $136.70 | 2019-2021 | |
| Janssen Products, LP | $118.85 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $108.26 | 2019-2020 | |
| Antares Pharma, INC. | $82.44 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $65.93 | 2021 | |
| Eisai INC. | $46.83 | 2020-2021 | |
| Dermira, INC. | $38.37 | 2020 | |
| Dynavax Technologies Corporation | $32.66 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.62 | 2019 | |
| Hologic Sales and Service, LLC | $23.56 | 2024 | Thinprep 2000 Processor, Aptima |
| Teva Pharmaceuticals USA, INC. | $18.48 | 2021 | |
| Amag Pharmaceuticals, INC. | $17.33 | 2020 | |
| Boston Scientific Corporation | $16.50 | 2024 | Varithena Administration Pack |
| Neuronetics, INC. | $15.63 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $14.67 | 2019 | |
| Tactile Systems Technology INC | $12.95 | 2019 | |
| Pfizer INC. | $10.93 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mia Scott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.